Nonrandom chromsome rearrangements in 27 cases of human myeloid leukemia

Rozynkowa, D; Stepien, J; Kowalewski, Jan; Nowakowski, Andrzej

doi:10.1007/bf00295422

Hum Genet

1977

DOI: 10.1007/bf00295422

|View full text |Cite

Nonrandom chromsome rearrangements in 27 cases of human myeloid leukemia

D Rozynkowa

J Stepien

Jan Kowalewski

et al.

Abstract: The R-banding pattern of the chromosomes of 31 patients hospitalized in the Hematologic Clinic for myeloid leukemia were studied before chemotherapy. This analysis permitted identification of one unusual 3-chromosome rearrangement t(3;9;22) in addition to 25 classic forms of (22q-;9q+) translocation accompanied by the specific Ph' chromosome in chronic granulocytic leukemia patients, independent of the blastic course of the disease. During blastic crisis observed in 6 patients, extra 8 and 10 chromosomes, mono… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1979

1982

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 13 publications

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Chromosomes and causation of human cancer and leukemia. XXXII. Unusual features of Ph1-positive acute myeloblastic leukemia (AML), including a review of the literature

Sandberg

1979

Cancer

View full text Add to dashboard Cite

Five cases of Ph1-positive AML were studied. In all cases a Ph1-chromosome was shown with banding techniques to be due to a translocation between chromosomes No. 9 and No. 22. Cases 1 and 4 were found to have more than one Ph1 with evidence of only on Ph1-translocation accompanying other chromosome abnormalities. Two cases represented an unusual pattern of appearance and disappearance of the Ph1-positive clone during their clinical courses: Case No. 2 was originally Ph1-positive (46,XY,Ph1) but two months before his expiration the Ph1-positive clone was completely replaced by a newly developed Ph1-negative clone with an abnormal chromosome No. 21 (46,XY,21q+), whereas case No. 3, primarily Ph1-negative, developed a Ph1-positive clone among the previously karyotypically normal cells one month before death. The Ph1-positive AML cases presented have been discussed in relation to: 1) the genesis and significance of the Ph1-positive clone, 2) differentiation from the blastic phase of CML and 31 the general experience with Ph1-positive acute non-lymphocytic leukemia (ANLL), the world literature of which have been tabulated.

show abstract

Chromosomes and causation of human cancer and leukemia. XXXII. Unusual features of Ph1-positive acute myeloblastic leukemia (AML), including a review of the literature

Sandberg

1979

Cancer

View full text Add to dashboard Cite

show abstract

Chromosomes and causation of human cancer and leukemia: XL. The Ph1 and other translocations in CML

Sandberg

1980

Cancer

119

View full text Add to dashboard Cite

To date, 85 cases with unusual Ph1 translocations have been described and are summarized in the present work. Of the 85 translocations, 41 were simple and 44 complex. Only chromosomes #1, #4, #8, and #20 and the Y have not been found to be involved in simple translocations and #12, #16, #18, #20 and the Y in complex ones. Chromosomes #18, #20, and Y have not been involved to date in either complex or simple Ph1 translocations. Four cases have been reported in whom more tan three chromosomes were involved in the Ph1 translocation and only four cases in whom the #9 was not involved in complex Ph1 translocations. The chromosomal changes, in addition to the Ph1, accompanying unusual Ph1 translocations in CML are not different from those seen in cases with the standard type of Ph1 translocation. Translocations (other than the Ph1) in CML occur in less than 1% of the cases and, to date, have found to involve all the chromosomes except the X and Y. With rare exceptions, in complex Ph1 translocations 1) the distal end of #22 is translocated to a third chromosome (i.e., other than #9), a part of which is translocated to #9, #2) the breaks in the involved chromosomes probably occur concomitantly, and 3) a characteristic PH1 chromosome is present. The survival of patients with CML and unusual or complex Ph1 translocations does not differ significantly from that of patients with the standard Ph1-translocation.

show abstract

Complex translocations between chromosomes #6, #9, #22, and #11 in a patient with chronic myelocytic leukemia: 46,XX,t(6;9;22;11)(p21;q34;q11;q13)

Carbonell

Kratt

Neuhaus

1980

Cancer Genetics and Cytogenetics

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Nonrandom chromsome rearrangements in 27 cases of human myeloid leukemia

Cited by 13 publications

References 22 publications

Chromosomes and causation of human cancer and leukemia. XXXII. Unusual features of Ph1-positive acute myeloblastic leukemia (AML), including a review of the literature

Chromosomes and causation of human cancer and leukemia. XXXII. Unusual features of Ph1-positive acute myeloblastic leukemia (AML), including a review of the literature

Chromosomes and causation of human cancer and leukemia: XL. The Ph1 and other translocations in CML

Complex translocations between chromosomes #6, #9, #22, and #11 in a patient with chronic myelocytic leukemia: 46,XX,t(6;9;22;11)(p21;q34;q11;q13)

Contact Info

Product

Resources

About